Immuneering Corporation
Immuneering Corporation (IMRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
imrx · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$12.00
+205.3% upside
Low
$12.00
Median: $12 · Last Close: $3.93
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.73 | ↓ 5.00% |
1-day model range: $3.69–$3.77. Peak: $3.77 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IMRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-19 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-09 | Needham | Maintains | Buy→Buy |
| 2025-11-13 | Chardan Capital | Maintains | Buy→Buy |
| 2025-09-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-09-26 | Chardan Capital | Maintains | Buy→Buy |
| 2025-09-25 | Oppenheimer | Maintains | Outperform→Outperform |
| 2025-09-15 | Needham | Maintains | Buy→Buy |
| 2025-08-26 | Needham | Maintains | Buy→Buy |
| 2025-08-14 | Chardan Capital | Maintains | Buy→Buy |
| 2025-06-18 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Immuneering Corporation (IMRX) stock. Of the recent 57 rating actions, 2 were upgrades and 4 were downgrades. 11 analysts currently cover IMRX.
Analyst Recommendation Trends
IMRX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$21M
↓ 58.9% YoY
Revenue Next Year
$16M
↓ 24.8% YoY
EPS This Year
$-1.14
EPS Next Year
$-1.34
↑ 17.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast IMRX EPS of $-1.14 for the current fiscal year, based on estimates from 5 analysts. The IMRX revenue forecast is $21M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IMRX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMRX price target is $12.00 (+205.3% upside), with an analyst consensus of Buy.
The IMRX short-term stock prediction for tomorrow is $3.73 (-5.00%).
Immuneering Corporation trades on NASDAQ under the ticker IMRX. The IMRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.
Frequently asked questions
IMRX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month IMRX price target is $12.00, with a high forecast of $12.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +205.3% potential upside from the current price of $3.93.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.